The DOI matches its Crossref record.
KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence
Open accessAbstract
Purpose: Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is known incompletely. Patients and Methods: We identified 11 population-based series of patients with GIST through a literature search and pooled individual data from 3,067 patients treated with macroscopically complete tumor excision. Mutation analysis was done from 1,505 tumors. We analyzed associations between KIT and PDGFRA mutations and recurrence-free survival (RFS) in the subsets in which patients were treated with surgery alone. Results: We identified 301 different single mutations in KIT and 33 in PDGFRA. Patients with PDGFRA mutations had more favorable RFS than those with KIT mutations (hazard ratio, 0.34; P = .004). Only one of the 35 GISTs with KIT exon 11 duplication mutations recurred. Patients with deletions of only one codon of KIT exon 11 had better RFS than those with another deletion type, and some KIT exon 11 substitution mutations (Trp557Arg, Val559Ala, and Leu576Pro) were also associated with favorable RFS. Patients with an identical mutation had greatly variable outcomes depending on the standard prognostic factors, notably, mitotic count. Commonly used risk stratification schemes tended to overestimate the risk for recurrence in subgroups with prognostically favorable mutations. Conclusion: GISTs with an identical KIT or PDGFRA mutation may have widely varying risks for recurrence. Most of the patients with PDGFRA mutations and those with KIT exon 11 duplication mutation or deletion of one codon have favorable RFS with surgery alone and are usually not candidates for adjuvant therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Role of PI3K/AKT pathway in cancer: the framework of malignant behavior
Jiang, N., Dai, Q., Su, X., Fu, J., Feng, X., & Peng, J. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05435-1 · Cited by 571
Nishida, T., Blay, J.-Y., Hirota, S., Kitagawa, Y., & Kang, Y.-K. (2016) · Gastric Cancer · doi:10.1007/s10120-015-0526-8 · Cited by 486
Self-citationGastrointestinal stromal tumours
Blay, J.-Y., Kang, Y.-K., Nishida, T., & von Mehren, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00254-5 · Cited by 460
Self-citationGastrointestinal Stromal Tumors
von Mehren, M., & Joensuu, H. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9705 · Cited by 306
Self-citationSmolle, M. A., Seidel, M. G., Kashofer, K., Liegl-Atzwanger, B., Sadoghi, P., Müller, D. A., & Leithner, A. (2025) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-024-05711-w · Cited by 16
Metadata
- Authors
- Joensuu, H., Rutkowski, P., Nishida, T., Steigen, S. E., Brabec, P., Plank, L., Nilsson, B., Braconi, C., Bordoni, A., Magnusson, M. K., Sufliarsky, J., Federico, M., Jonasson, J. G., Hostein, I., Bringuier, P.-P., & Emile, J.-F.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-02-20
- Volume
- 33
- Issue
- 6
- Pages
- 634-642
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2141445760
- Cited by
- 176
- References
- 0
- FWCI
- 18.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence. https://app.cochat.ai/papers/10.1200/jco.2014.57.4970
- The paper
- Joensuu, H., Rutkowski, P., Nishida, T., Steigen, S. E., Brabec, P., Plank, L., Nilsson, B., Braconi, C., Bordoni, A., Magnusson, M. K., Sufliarsky, J., Federico, M., Jonasson, J. G., Hostein, I., Bringuier, P.-P., & Emile, J.-F. (2015). KIT and PDGFRA Mutations and the Risk of GI Stromal Tumor Recurrence. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.57.4970
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.